Regenerative Surgical Treatment of Peri-implantitis
Launched by CATRINE ISEHED · Jul 15, 2015
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
This is a randomised controlled clinical trial. Recruiting 31 patient with periimplantitis at one or more implants in need for surgical treatment.
Randomisation to test group (EMD) with surgical treatment and additional application of enamel matrix derivative (Emdogain®) or surgical treatment alone in the control group (non-EMD).
Treatment of existing periodontitis performed before recruitment. Baseline examination including samples of microbiota and peri-implant fluid followed by surgical treatment. Access surgery to remove chronic inflammatory tissue and clean the implant surface from b...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • peri-implant angular bone loss ≥3 mm, measured at radiographs
- • deep pocket ≥5 mm combined with bleeding and/or pus
- Exclusion Criteria:
- • individuals with uncontrolled diabetes (HbA1c \> 7,0%)
- • individuals where prophylaxis of antibiotic is indicated
- • medication with prednisolon or other anti-inflammatory drug
- • medication with gingival hyperplasia known as a side effect
- • systemic antibiotic intake the last 3 months
About Catrine Isehed
Catrine Isehed is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a strong focus on operational excellence and regulatory compliance, Catrine Isehed collaborates with leading research institutions and healthcare providers to design and implement clinical trials that address unmet medical needs. The organization emphasizes a patient-centric approach, prioritizing safety and efficacy while fostering transparency and integrity in all phases of clinical development. Through strategic partnerships and a robust portfolio of research initiatives, Catrine Isehed aims to contribute to the evolution of healthcare and the discovery of groundbreaking treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gävle, , Sweden
Patients applied
Trial Officials
Pernilla Lundberg, Assoc. Prof
Principal Investigator
Department of Odontology, Division of Molecular Periodontology , Umeå University, Sweden, pernilla.lundberg@umu.se
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials